Opko Health (OPK) Price & Analysis

Compare

3,290 Followers

OPK Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.11 - $2.04

Previous CloseN/A

Volume574.71K

Average Volume (3M)2.69M

Market Cap

$1.07B

Enterprise Value$1.16B

Total Cash (Recent Filing)$271.72M

Total Debt (Recent Filing)$395.74M

Price to Earnings (P/E)―

Beta0.86

Next Earnings

Nov 05, 2025

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding793,782,800

10 Day Avg. Volume3,604,149

30 Day Avg. Volume2,686,097

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)0.75

Price to Sales (P/S)1.43

P/FCF Ratio-4.89

Enterprise Value/Market Cap1.09

Enterprise Value/Revenue1.75

Enterprise Value/Gross Profit5.37

Enterprise Value/Ebitda19.56

Forecast

1Y Price Target

$2.89

Price Target Upside114.07% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Operational ImprovementThe operating loss in the lab business narrowed from $23.9 million in Q1 to $18.2 million in Q2, showing operational improvement.

Product GrowthRecent prescription trends for OPKO’s once weekly hGH product, NGENLA, are positive, with solid growth expected.

Strategic PartnershipsLabcorp transaction expected to close, potentially streamlining operations and strengthening cash position for OPKO.

Bears Say

Financial PerformanceTotal revenue of $156.8 million was lower than the estimate of $165.3 million, indicating weaker financial performance.

Guidance ReductionManagement slightly reduced certain elements of its financial guidance for the fiscal year, including total revenue and NGENLA gross profit share.

Revenue DeclineDiagnostic services revenue was $101.1M, representing a 21.9% YoY decline due to lower clinical test volume from asset sales.

Opko Health News

Optimistic Growth Prospects for OPKO Health: Buy Rating with 89% Upside Potential

Opko Health, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Petusky from...

12d ago

OPK

OPKO Health’s Earnings Call: Strategic Moves Amid Challenges

Opko Health (($OPK)) has held its Q2 earnings call. Read on for the main highlights of the call....

14d ago

OPK

Opko Health: Strategic Moves and Future Prospects Drive Buy Rating Amid Revenue Challenges

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Opko Health, with...

15d ago

OPK

OPKO Health Reports Q2 2025 Financial Results and Developments

Opko Health ( ($OPK) ) has released its Q2 earnings. Here is a breakdown of the information Opko...

15d ago

OPK

Is OPK a Buy, Before Earnings?

Opko Health (OPK) is scheduled to report 2nd quarter earnings on 07/31/2025, after the market closes. Regarding Q2...

18d ago

OPK

Entera Bio, Opko Health announce new in vivo data for OPK-88006

OPKO Health (OPK) and Entera Bio (ENTX) announced that new pharmacologic and pharmacokinetic in vivo data for investigational...

2M ago

OPK

ENTX

Opko Health, Entera Bio say OPK-88006 data selected for ENDO 2025

OPKO Health (OPK) and Entera Bio (ENTX) announced that new pharmacologic and pharmacokinetic in vivo data for investigational...

2M ago

OPK

ENTX

Opko Health’s ModeX forms Scientific Advisory Board

ModeX Therapeutics announced the creation of a Scientific Advisory Board to provide counsel and insight into the development...

2M ago

OPK

Opko Health Grants Stock Options and Bonuses

Opko Health ( ($OPK) ) has provided an announcement. On May 27, 2025, Opko Health‘s Compensation Committee granted...

3M ago

OPK

OPKO Health’s Earnings Call: Mixed Sentiments and Strategic Moves

Opko Health (($OPK)) has held its Q1 earnings call. Read on for the main highlights of the call....

4M ago

OPK

Optimistic Buy Rating for Opko Health Driven by Strategic Developments and Future Prospects

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Opko Health (OPK – Research Report), retaining...

4M ago

OPK

OPKO Health Reports Q1 2025 Financial Highlights

Opko Health ( ($OPK) ) has released its Q1 earnings. Here is a breakdown of the information Opko...

4M ago

OPK

Opko Health (OPK) Q1 Earnings Cheat Sheet

Opko Health (OPK) is scheduled to report 1st quarter earnings on 04/30/2025, after the market closes. Regarding Q1...

4M ago

OPK

Keurig upgraded, Global Payments downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

4M ago

OPK FAQ

What was Opko Health Inc’s price range in the past 12 months?

Opko Health Inc lowest stock price was $1.11 and its highest was $2.04 in the past 12 months.

What is Opko Health Inc’s market cap?

Opko Health Inc’s market cap is $1.07B.

When is Opko Health Inc’s upcoming earnings report date?

Opko Health Inc’s upcoming earnings report date is Nov 05, 2025 which is in 81 days.

How were Opko Health Inc’s earnings last quarter?

Opko Health Inc released its earnings results on Jul 31, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.113 by -$0.077.

Is Opko Health Inc overvalued?

According to Wall Street analysts Opko Health Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Opko Health Inc pay dividends?

Opko Health Inc does not currently pay dividends.

What is Opko Health Inc’s EPS estimate?

Opko Health Inc’s EPS estimate is -0.08.

How many shares outstanding does Opko Health Inc have?

Opko Health Inc has 793,782,800 shares outstanding.

What happened to Opko Health Inc’s price movement after its last earnings report?

Opko Health Inc reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.113. Following the earnings report the stock price went down -7.031%.

Which hedge fund is a major shareholder of Opko Health Inc?

Currently, no hedge funds are holding shares in OPK

Opko Health Stock Smart Score

Neutral

Fundamentals

Return on Equity

-13.16%

Trailing 12-Months

Asset Growth

-0.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Opko Health Inc

Opko Health, Inc. is a diversified healthcare company focused on the development and commercialization of innovative and proprietary pharmaceuticals, diagnostics, and biologics. The company operates primarily in two segments: pharmaceuticals and diagnostics. Opko's pharmaceutical offerings include products for various therapeutic areas, including urology, endocrinology, and ophthalmology, while its diagnostics segment features advanced laboratory services and diagnostic tests, including the 4Kscore test for prostate cancer risk assessment.

Opko Health (OPK) Earnings & Revenues

Historic Earnings Reports

OPK Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant strategic moves, such as the sale of the oncology business and FDA approval for the 4Kscore test, indicating strong steps towards future profitability. However, these positives are tempered by ongoing revenue challenges in the Diagnostics segment and increased operating losses in the Pharmaceutical segment, as well as the slower-than-expected adoption of key products.View all OPK earnings summaries

OPK Stock 12 Month Forecast

Average Price Target

$2.89

▲(114.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","1.5":"$1.5","4.5":"$4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.19,1.4984615384615383,1.8069230769230769,2.1153846153846154,2.4238461538461538,2.732307692307692,3.0407692307692304,3.3492307692307692,3.6576923076923076,3.966153846153846,4.274615384615384,4.5830769230769235,4.891538461538461,{"y":5.2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.19,1.3207692307692307,1.4515384615384614,1.5823076923076922,1.713076923076923,1.8438461538461537,1.9746153846153847,2.105384615384615,2.2361538461538464,2.3669230769230767,2.497692307692308,2.628461538461538,2.7592307692307694,{"y":2.89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.19,1.1753846153846153,1.1607692307692308,1.146153846153846,1.1315384615384616,1.116923076923077,1.1023076923076922,1.0876923076923077,1.073076923076923,1.0584615384615383,1.0438461538461539,1.0292307692307692,1.0146153846153847,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.23,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >